Intellia Therapeutics Inc (FRA:38I)
€ 21.68 -0.35 (-1.59%) Market Cap: 2.05 Bil Enterprise Value: 1.42 Bil PE Ratio: 0 PB Ratio: 2.15 GF Score: 56/100

Intellia Therapeutics Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) Transcript

May 30, 2023 / 03:30PM GMT
Release Date Price: €37.23 (+4.02%)
Dae Gon Ha
Stifel Nicolaus - Stifel Financial Corp - Analyst

Great. Good morning, everyone. Thanks for continuing to join us for the next fireside chat. My name is Dae Gon Ha, one of the biotech analysts here at Stifel. For the next half hour, we have the pleasure of discussing Intellia. And from Intellia, we have the Chief Scientific Officer, Dr. Laura Sepp-Lorenzino.

So Laura, thank you very much for your time today.

Laura Sepp;Lorenzino
Intellia Therapeutics, Inc. - EVP, Chief Scientific Officer

Thank you for having me. This is great.

Questions & Answers

Dae Gon Ha;Laura Sepp;Lorenzino
Stifel Nicolaus - Stifel Financial Corp - Analyst;Intellia

So as we do with all of these fireside chats, maybe we'll start off at a high level. If you can just remind us what you guys are up to, some of the catalysts that we're looking forward to, whether it's clinical, regulatory, or anything of the sort, in the next, say, 12 to 18 months.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot